BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosenbach Y, Hartman C, Shapiro R, Hirsch A, Avitzur Y, Shamir R. Adalimumab treatment in children with refractory Crohn’s disease. Dig Dis Sci. 2010;55:747-753. [PMID: 19333754 DOI: 10.1007/s10620-009-0791-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2927-36. [PMID: 23867874 DOI: 10.1097/MIB.0b013e31829aad16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
2 Smith EM, Foster HE, Beresford MW. The development and assessment of biological treatments for children. Br J Clin Pharmacol 2015;79:379-94. [PMID: 24750505 DOI: 10.1111/bcp.12406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Szymanska E, Dadalski M, Szymanska S, Grajkowska W, Pronicki M, Kierkus J. The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn's disease. Prz Gastroenterol 2016;11:176-80. [PMID: 27713779 DOI: 10.5114/pg.2016.57753] [Reference Citation Analysis]
4 Navas-lópez VM, Pujol-muncunill G, Llerena E, Navalón Rubio M, Gil-ortega D, Varea-calderón V, Sierra Salinas C, Martin-de-carpi J. A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease. Anales de Pediatría (English Edition) 2018;88:89-99. [DOI: 10.1016/j.anpede.2017.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Nuti F, Fiorino G, Danese S. Adalimumab for the treatment of pediatric Crohn’s disease. Expert Review of Clinical Immunology 2015;11:963-72. [DOI: 10.1586/1744666x.2015.1072048] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
6 Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 2013;57:1318-30. [PMID: 23899685 DOI: 10.1093/cid/cit489] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
7 Penagini F, Cococcioni L, Pozzi E, Dilillo D, Rendo G, Mantegazza C, Zuccotti GV. Biological therapy in pediatric age. Pharmacol Res 2020;161:105120. [PMID: 32783974 DOI: 10.1016/j.phrs.2020.105120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA, Colletti RB, Dubinsky M, Kierkus J, Rosh J, Wang Y. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012;143:365-374.e2. [PMID: 22562021 DOI: 10.1053/j.gastro.2012.04.046] [Cited by in Crossref: 158] [Cited by in F6Publishing: 131] [Article Influence: 15.8] [Reference Citation Analysis]
9 Gouldthorpe O, Catto-Smith AG, Alex G. Biologics in paediatric Crohn's disease. Gastroenterol Res Pract 2011;2011:287574. [PMID: 22144993 DOI: 10.1155/2011/287574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
10 Lahad A, Weiss B. Current therapy of pediatric Crohn’s disease. World J Gastrointest Pathophysiol 2015; 6(2): 33-42 [PMID: 25977836 DOI: 10.4291/wjgp.v6.i2.33] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
11 Truffinet O, Martinez-vinson C, Guerriero E, Hugot J, Viala J. Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease: A Case Series. Journal of Pediatric Gastroenterology & Nutrition 2017;64:721-5. [DOI: 10.1097/mpg.0000000000001338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
12 Martín-de-Carpi J, Pociello N, Varea V. Long-term efficacy of adalimumab in paediatric Crohn’s disease patients naïve to other anti-TNF therapies. J Crohns Colitis. 2010;4:594-598. [PMID: 21122566 DOI: 10.1016/j.crohns.2010.04.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
13 Nobile S, Gionchetti P, Rizzello F, Calabrese C, Campieri M. Mucosal healing in pediatric Crohn’s disease after anti-TNF therapy: a long-term experience at a single center. European Journal of Gastroenterology & Hepatology 2014;26:458-65. [DOI: 10.1097/meg.0000000000000045] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Carnovale C, Maffioli A, Zaffaroni G, Mazhar F, Battini V, Mosini G, Pozzi M, Radice S, Clementi E, Danelli P. Efficacy of Tumour Necrosis Factor-alpha therapy in paediatric Crohn's disease patients with perianal lesions: a systematic review. Expert Opin Biol Ther 2020;20:239-51. [PMID: 31971447 DOI: 10.1080/14712598.2020.1718096] [Reference Citation Analysis]
15 Lapadula G, Marchesoni A, Armuzzi A, Blandizzi C, Caporali R, Chimenti S, Cimaz R, Cimino L, Gionchetti P, Girolomoni G, Lionetti P, Marcellusi A, Mennini FS, Salvarani C. Adalimumab in the treatment of immune-mediated diseases. Int J Immunopathol Pharmacol 2014;27:33-48. [PMID: 24774505 DOI: 10.1177/03946320140270S103] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
16 Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443-1451; quiz e88-9. [PMID: 24462626 DOI: 10.1016/j.cgh.2014.01.021] [Cited by in Crossref: 94] [Cited by in F6Publishing: 79] [Article Influence: 11.8] [Reference Citation Analysis]
17 Kierkuś J, Iwańczak B, Wegner A, Dadalski M, Grzybowska-Chlebowczyk U, Łazowska I, Maślana J, Toporowska-Kowalska E, Czaja-Bulsa G, Mierzwa G, Korczowski B, Czkwianianc E, Żabka A, Szymańska E, Krzesiek E, Więcek S, Sładek M. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease. J Pediatr Gastroenterol Nutr 2015;60:580-5. [PMID: 25564804 DOI: 10.1097/MPG.0000000000000684] [Cited by in Crossref: 37] [Cited by in F6Publishing: 9] [Article Influence: 6.2] [Reference Citation Analysis]
18 Malik S, Ahmed SF, Wilson ML, Shah N, Loganathan S, Naik S, Bourke B, Thomas A, Akobeng AK, Fagbemi A. The effects of anti-TNF-α treatment with adalimumab on growth in children with Crohn’s disease (CD). J Crohns Colitis. 2012;6:337-344. [PMID: 22405171 DOI: 10.1016/j.crohns.2011.09.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
19 Assa A, Hartman C, Weiss B, Broide E, Rosenbach Y, Zevit N, Bujanover Y, Shamir R. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. J Crohns Colitis. 2013;7:369-376. [PMID: 22483567 DOI: 10.1016/j.crohns.2012.03.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 6.8] [Reference Citation Analysis]
20 Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106:674-684. [PMID: 21407178 DOI: 10.1038/ajg.2011.60] [Cited by in Crossref: 251] [Cited by in F6Publishing: 226] [Article Influence: 22.8] [Reference Citation Analysis]
21 Dziechciarz P, Horvath A, Kierkuś J. Efficacy and Safety of Adalimumab for Paediatric Crohn's Disease: A Systematic Review. J Crohns Colitis 2016;10:1237-44. [PMID: 26995184 DOI: 10.1093/ecco-jcc/jjw077] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
22 Cameron FL, Altowati MA, Rogers P, Mcgrogan P, Anderson N, Bisset WM, Ahmed SF, Wilson DC, Russell RK. Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2017;64:47-55. [DOI: 10.1097/mpg.0000000000001379] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
23 Russell RK, Wilson ML, Loganathan S, Bourke B, Kiparissi F, Mahdi G, Torrente F, Rodrigues A, Davies I, Thomas A. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:946-953. [PMID: 21342211 DOI: 10.1111/j.1365-2036.2011.04603.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
24 de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:985-1002. [PMID: 21936033 DOI: 10.1002/ibd.21871] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
25 Zeisler B, Hyams JS. Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab. Pediatric Health Med Ther 2015;6:33-40. [PMID: 29388607 DOI: 10.2147/PHMT.S40948] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Esposito S, Antoniol G, Labate M, Passadore L, Alvisi P, Daccò V, Ghizzi C, Colombo C, Principi N. Vaccines in Children with Inflammatory Bowel Disease: Brief Review. Vaccines (Basel) 2021;9:487. [PMID: 34064576 DOI: 10.3390/vaccines9050487] [Reference Citation Analysis]
27 Pichler J, Huber WD, Aufricht C, Bidmon-Fliegenschnee B. Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody. World J Gastroenterol 2015; 21(21): 6613-6620 [PMID: 26074699 DOI: 10.3748/wjg.v21.i21.6613] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
28 Fumery M, Jacob A, Sarter H, Michaud L, Spyckerelle C, Mouterde O, Savoye G, Colombel J, Peyrin-biroulet L, Gower-rousseau C, Turck D. Efficacy and Safety of Adalimumab After Infliximab Failure in Pediatric Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2015;60:744-8. [DOI: 10.1097/mpg.0000000000000713] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
29 Kierkus J, Szymanska E, Oracz G, Wiernicka A, Dadalski M. Profile of infliximab in the treatment of pediatric Crohn's disease. Pediatric Health Med Ther 2015;6:79-85. [PMID: 29388577 DOI: 10.2147/PHMT.S64943] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Choi SY, Kang B. Adalimumab in Pediatric Inflammatory Bowel Disease. Front Pediatr 2022;10:852580. [DOI: 10.3389/fped.2022.852580] [Reference Citation Analysis]